What are the precautions for taking Relugolix?

In clinical studies of Relugolix, warnings and precautions such as QT/QTc interval prolongation, allergic reactions, and embryo-fetal toxicity have emerged.

1. Prolongation of QT/QTc interval: Androgen deprivation therapy (such as Repagliflox) may prolong the QT/QTc interval. Providers should consider whether the benefits of androgen deprivation therapy outweigh its potential risks in patients with congenital long QT syndrome, congestive heart failure, or recurrent electrolyte abnormalities and in patients taking drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected. Consider regular EKG and electrolyte monitoring.

2. Allergic reaction: Patients who are severely allergic to relugolix or any product ingredients are prohibited from taking relugolix. After the marketing of Repagliflozin, allergic reactions, including pharyngeal edema and other severe angioedema, occurred in patients treated with Repagliflozin. Angioedema has also been reported in studies. Patients who experience any allergic symptoms are advised to temporarily stop taking Ripagliflox and seek medical attention immediately. For severe allergic reactions, discontinue use of Repagliflozin and manage as clinically indicated.

3. Embryo-Fetal Toxicity: According to animal research results and mechanism of action, for example, Regolic can cause fetal damage and miscarriage when used in pregnant women. In an animal reproduction study, oral administration of Repagliflozin to pregnant rabbits during the period of organogenesis resulted in maternally exposed embryonic-fetal lethality that was 0.3 times higher than human exposure at the recommended daily dose of 120 mg. Men who are partners of a female of potential reproductive potential are therefore advised to use effective contraception during treatment and for 2 weeks after the last dose of Repagliflozin.